Loading...
Dernières publications
-
Luce Barbat Du Closel, Nathalie Bonello-Palot, Yann Pereon, Andoni Echaniz-Laguna, Jean Philippe Camdessanche, et al.. Clinical and electrophysiological characteristics of women with X-linked Charcot-Marie-Tooth disease. European Journal of Neurology, 2023, 30 (10), pp.3265-3276. ⟨10.1111/ene.15937⟩. ⟨hal-04254200⟩
-
-
Joe-Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Leonard-Louis, Stéphane Ederhy, et al.. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discovery, 2023, 13 (5), pp.1100-1115. ⟨10.1158/2159-8290.CD-22-1180⟩. ⟨hal-04578810⟩
-
-
Corinna Preuße, Barbara Paesler, Christopher Nelke, Derya Cengiz, Thomas Müntefering, et al.. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144 (2), pp.353-372. ⟨10.1007/s00401-022-02438-z⟩. ⟨hal-03830925⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-03832478⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-04002766⟩
-
-
Stéphane Ederhy, Perrine Devos, Bruno Pinna, Elisa Funck-Brentano, Baptiste Abbar, et al.. 8 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography imaging for the diagnosis of immune checkpoint inhibitors associated myocarditis. Archives of cardiovascular diseases, 2022, ⟨10.1016/j.acvd.2021.12.001⟩. ⟨hal-03561783⟩
-
Chiffres clés
123
Publications avec texte intégral
Open Access
53 %
Mots clés
Data integration
Aged
Antisynthetase
AAV vector
Adolescence
Prognosis
Lysosomal storage diseases
Anti-interleukin-6
Adeno-associated vector
Acute Kidney Injury/epidemiology/etiology
Gene therapy
Biopsy
Cardio-oncology
Inflammation
Assisted communication devices
Autoimmunity
Active
Abnormal movement
Auto-immunité
Immune checkpoint inhibitors
Auto-antibodies
Anticorps anti-agalsidase
DM
Inflammatory myopathy
COVID-19
Cytokines
Anti-drug antibodies
IBM
Middle Aged
Biomarqueurs
Female
Multidisciplinarity
Systems biology
Adeno-associated virus
Polymyositis
IMNM
Case reports
Arthritis
Autoimmune diseases
Male
Myocarditis
B cell homeostasis
Auto‐antibodies
Deep immune profiling
Analyses multidimensionnelles
Myopathy
Dependovirus/genetics/immunology
Myositis and muscle disease
Outcome measures
Interferon
Mass cytometry
Anti-IgE IgG
Acid-alpha-glucosidase
Anti‐mitochondrial antibodies
Anti-MDA5 autoantibodies
Amyotrophic lateral sclerosis
Anti-Mi2
Muscle
Adverse drug reactions
Antibodies
Machine learning
AAV
Idiopathic inflammatory myopathies
Agalsidase
Skeletal muscle
Adult
Bioelectrical impedance analysis
Fabry disease
Biomarkers
Biomarker
Antibody responses
Inborn errors of metabolism
Cancer
Myositis
Inclusion body myositis
Anticorps spécifique des myosites
Dermatomyositis
Aldosterone
Adeno-associated virus vector
Humans
Anémie hémolytique
Interstitial lung disease
Amyotrophy
Immunotherapy
Pharmacology
Autoantibodies
Antiphospholipid syndrome
Anti-synthetase syndrome
Anti-agalsidase antibodies
AAV humoral immunity
Autoantibody
AAV antibody
Aldostérone
Adjudication
B-lymphocyte
Antisynthétase
Sphingosine-1-phosphate
Animals
Antisynthetase syndrome
AAV vectors